Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NXY-059. Centaur.

Paul A Lapchak1

  • 1UCSD Neuroscience MTF 316, 9500 Gilman Drive, La Jolla, CA 92093-0624, USA. plapchak@ucsd.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|January 17, 2003
PubMed
Summary

NXY-059, a free radical trapping agent, is being developed to treat reperfusion injury after stroke. Clinical trials are underway, with Phase III studies for acute stroke planned.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CNB-001 reduces paraplegia in rabbits following spinal cord ischemia.

Neural regeneration research·2019
Same author

CNB-001, a pleiotropic drug is efficacious in embolized agyrencephalic New Zealand white rabbits and ischemic gyrencephalic cynomolgus monkeys.

Experimental neurology·2018
Same author

Intravenous xenogeneic human cardiosphere-derived cell extracellular vesicles (exosomes) improves behavioral function in small-clot embolized rabbits.

Experimental neurology·2018
Same author

Cytoprotective Drug-Tissue Plasminogen Activator Protease Interaction Assays: Screening of Two Novel Cytoprotective Chromones.

Translational stroke research·2017
Same author

Translational Stroke Research Guideline Projections: The 20/20 Standards.

Translational stroke research·2017
Same author

Data Standardization and Quality Management.

Translational stroke research·2017

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Reperfusion injury following stroke is a significant cause of neurological damage.
  • Free radical damage plays a critical role in the pathophysiology of ischemic stroke.

Purpose of the Study:

  • To evaluate the efficacy and safety of NXY-059 as a potential therapy for acute ischemic stroke.
  • To investigate the role of free radical trapping in mitigating reperfusion injury.

Main Methods:

  • NXY-059, an alpha-phenyl-N-tert-butyl nitrone derivative, functions as a free radical trapping agent.
  • Ongoing Phase II clinical trials are assessing the therapeutic potential of NXY-059.
  • Phase III trials in acute stroke patients are planned for early 2003.

Main Results:

  • Data from ongoing trials will determine the efficacy of NXY-059 in reducing stroke-related damage.
  • Safety and tolerability profiles are being evaluated in current clinical studies.

Conclusions:

  • NXY-059 shows promise as a novel therapeutic agent for stroke.
  • Further clinical investigation, including Phase III trials, is warranted to establish its role in stroke management.

Related Experiment Videos